| Estimation of the dose of fluticasone propionate inhaled by infants after bronchiolitis: Effect on urinary cortisol excretion. | |
| | |
MedLine Citation:
|
PMID: 12417880 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
BACKGROUND: Information on the dose of steroid infants inhale from spacer devices and its potential effect on adrenal suppression is limited. OBJECTIVE: We sought to determine the total dose of fluticasone propionate (FP) inhaled from a spacer device (Babyhaler) with face mask attachment by infants recovering from acute bronchiolitis and the effect of inhaled FP on the infants' overnight urinary cortisol/creatinine ratios (UCCRs). METHODS: Infants studied were recovering from acute bronchiolitis. In study 1, 22 infants inhaled 150 microg of FP through the Babyhaler. The likely inhaled dose was estimated by trapping it on a filter held within the face mask. In study 2, 40 infants had UCCRs measured before and during 3 months of treatment with either FP (150 microg twice daily, n = 20) or placebo (n = 20). RESULTS: In study 1 the mean +/- SD dose of captured FP was 12.8 +/- 6.9 microg (ie, 2.1 +/- 1.2 microg/kg). In study 2 the pretreatment UCCR medians (interquartile ranges) were as follows: FP, 22.8 (23.0) nmol/mmol; placebo, 24.0 (28.3) nmol/mmol. Within-group UCCR changes (median and interquartile range DeltaUCCR) were significantly different in the FP group (-8.9 and -20.6 nmol/mmol at 6 weeks and -12.6 and -25.9 nmol/mmol at 12 weeks, respectively; P =.0008) but not in the placebo group ( -5.8 and -10.7 nmol/mmol at 6 weeks and +0.3 and -17.9 nmol/mmol at 12 weeks, respectively; P =.45). Intergroup changes were insignificant in the follow-up period (6 weeks, P =.52; 12 weeks, P =.19). CONCLUSION: After bronchiolitis, infants are likely to inhale approximately 8 % of the nominal steroid dose from the Babyhaler. UCCRs can be used to monitor the bioavailability of inhaled steroids in young infants. |
| | |
Authors:
|
Jackson Wong; Tim Davies; Christopher O'Callaghan |
Publication Detail:
|
Type: Clinical Trial; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't |
Journal Detail:
|
Title: The Journal of allergy and clinical immunology Volume: 110 ISSN: 0091-6749 ISO Abbreviation: J. Allergy Clin. Immunol. Publication Date: 2002 Nov |
Date Detail:
|
Created Date: 2002-11-05 Completed Date: 2002-12-19 Revised Date: 2006-11-15 |
Medline Journal Info:
|
Nlm Unique ID: 1275002 Medline TA: J Allergy Clin Immunol Country: United States |
Other Details:
|
Languages: eng Pagination: 721-7 Citation Subset: AIM; IM |
Affiliation:
|
Department of Child Health and Institute of Lung Health, University of Leicester, Clinical Sciences Building, Leicester Royal Infirmary, United Kingdom. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Acute Disease Administration, Inhalation Androstadienes / administration & dosage*, pharmacokinetics*, therapeutic use Anti-Inflammatory Agents / administration & dosage*, pharmacokinetics*, therapeutic use Bronchiolitis / drug therapy*, urine Creatinine / urine Double-Blind Method Humans Hydrocortisone / urine* Infant Infant, Newborn Metered Dose Inhalers Time Factors |
| Chemical | |
Reg. No./Substance:
|
0/Androstadienes; 0/Anti-Inflammatory Agents; 50-23-7/Hydrocortisone; 60-27-5/Creatinine; 90566-53-3/fluticasone |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: A methacholine challenge dose-response study for development of a pharmacodynamic bioequivalence met...
Next Document: The effect of anti-IgE treatment on in vitro leukotriene release in children with seasonal allergic ...